Tris(1,3-dichloro-2-propyl)phosphate (Tris-CP) was metabolized to products which were mutagenic for Salmonella typhimurium TA100 in the presence of liver microsomes from phenobarbital (PB)-pretreated rats and NADPH. Effects of various inhibitors and inducers of cytochrome P-450 on Tris-CP mutagenicity were in accordance with PB-inducible forms of this enzyme system being responsible for the formation of mutagenic product(s). A comparison was made between the toxic potential of the two halogenated flame retardants Tris-CP and tris(2,3-dibromopropyl)phosphate (Tris-BP) in 5 in vitro tests. Tris-CP was much less potent than Tris-BP with respect to bacterial (Salmonella/microsome or Salmonella/hepatocyte assay) and mammalian (V79 cells) mutagenicity, as well as DNA repair synthesis in hepatocytes. On the other hand, Tris-CP and Tris-BP were both equally effective in transforming Syrian hamster embryo cells in vitro. Tris-CP was not nephrotoxic to rats after a single dose of 500 mg/kg intraperitoneally, whereas Tris-BP caused extensive tubular necrosis accompanied by elevated levels of plasma urea and creatinine.
No takes yet. Share an insight, caveat, or question.
Sederlund et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: